Erica Partridge Parkinson’s Disease. Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis.

Slides:



Advertisements
Similar presentations
Pharmacological Management of Parkinson’s Disease
Advertisements

Parkinsons Disease Management in Primary Care. Introduction Progressive condition 1:500 whole population 1:50 of elderly 1:10 Nursing Home Residents.
Linda Pituch, Patient Services Manager, Parkinson’s Disease Foundation
Evaluation of Movement Disorders
Parkinson’s Finding the cure Presentation
Diagnosis and Management of Parkinson’s Disease
Parkinson’s Disease (PD)
The PARticulars of Parkinson’s Disease
Parkinson’s Disease Dr Rachel Cary, Warwick Hospital.
Idiopathic parkinson’s disease (IPD)
Basal Ganglia: PATHOLOGIES Emma & Amrit. PARKINSON’S HUNTONGTON’S BALISMUS/HEMIBALISMUS ATHETOSIS WILSON’S DISEASE.
Diagnosis and Treatment of Parkinson’s Disease Jeff Bronstein, MD, PhD Professor of Neurology at UCLA Director of the SW PADRECC Director of UCLA Movement.
Drugs Used to Treat Parkinson’s Disease By Jasmine and Morgan 11/13/03.
PHL 437/Pharmacogenomics Fourth Lecture (Parkinson’s disease) By Abdelkader Ashour, Ph.D. Phone:
Paul Short, Ph.D. The Parkinson’s Coach NEUROPSYCHOLOGY OF PARKINSON’S COMMUNICATION PROBLEMS.
Initial Diagnosis and Management of Parkinson’s Disease
Harald Bjorndalen Adapted from lecture by Dr Zoe Campbell (Medical SpR)
Parkinson’s Disease By Nik Sanyal.
Parkinson’s Disease and Treatment Shalla Hanson Medicinal Chemistry April 2009.
Basal ganglia & cerebellar pathology
Parkinson ’ s disease. Function Anatomy of Parkinson ’ s Disease.
JP Parkinson’s Disease. Overview Idiopathic PD Clinically and pathologically distinct from other parkinsonian syndromes Degenerative disorder of the CNS.
Parkinson’s Disease By Devin Cornford
SYMPTOM CONTROL IN ADVANCED PARKINSON’S DISEASE Vicky Travers PDNSUHMBT April 2012.
Parkinson’s Disease. Definition Parkinson's disease (PD) is an idiopathic, slowly progressive, neurodegenerative disorder whereby two or more of the following.
Treatment of Parkinson’s Disease Thomas L. Davis, M.D. Associate Professor of Neurology Vanderbilt School of Medicine.
Parkinson’s Disease superKAT :).
Alzheimer’s Disease The most common cause of Dementia –Progressive Memory Loss Plus loss in one other area of cognition: Perception Attention Language/Symbols.
By Prof. Hanan Hagar Pharmacology unit Medical College.
Surgery for Parkinson’s Disease: Focus on Deep Brain Stimulation Ramón L Rodríguez, MD Director of Clinical Services University of Florida Movement Disorders.
Adult Medical-Surgical Nursing Neurology Module: Parkinson’s Disease.
Treatment of Parkinson Disease David Tran, 2013 Mercer University PharmD Candidate.
Salvador Dali (Painter) Mao Zedong (Chinese Politician) Michael J Fox (Actor) Pope John Paul II Muhammad Ali (Boxer) Janet Reno (Former AG)
Treatment of Parkinson’s Disease Christopher Buchanan CHEM 5398/Buynak April 3, 2007.
Mostly Parkinson’s disease but also few other movement disorders due to diseases of the basal ganglia.
Richard Leckey Oct 2,2015.  Faculty: Dr. Richard Leckey  Relationships with commercial interests:  Biogen  Merck  Serono  Novartis  Allergen CFPC.
PARKINSON’S DISEASE By: AARUSHI JAIN AMRUTA KAMBLE ANNETT MARY JACOB AVANTI DEO M.Sc. PRIST (09-11)
 Parkinson’s Disease (PD) -progressive neurodegenerative disease affecting motor ability -third most common neurologic disorder of older adults.
By: Alejandro Navarro and Andrea Ors. Content Introduction What is Parkinson's disease? What causes the disease? History Main symptoms Treatment Statistics.
Parkinson's disease By Colby Allen. symptoms Mild to major tremors. Rigidity or joint stiffness Bradykinesia or slowness of movement Postural instability.
PARKINSON’S DISEASE.
Parkinson’s Disease Angela Duncan June Why I Chose This Subject Common neurodegenerative disorder / in Scotland Expected increase.
Drugs Used for Parkinson’s Disease Chapter 15 Mosby items and derived items © 2010, 2007, 2004 by Mosby, Inc., an affiliate of Elsevier Inc.
Pathogenesis and pathology of parkinsonism
ANTI- PARKINSONISM Dr: Samah Gaafar Al-shaygi.  Neurodegenerative diseases.  Dopamenergic neurones in substantia nigra.  Environmental* genetic factors.
Primary Symptoms It is important to note that not all patients experience the full range of symptoms; in fact, most do not. Rigidity is an increased tone.
ANTI-PARKINSONIAN DRUGS. Parkinsonism It is a common movement disorder that involves dysfunction in the basal ganglia and associated brain structures.
Parkinson's disease ♦ Is a neurodegenerative disorder ♦ Develops around age 50 * incidence rises with age * affects 1-2% of population > age 65 ♦ Higher.
PARKINSON’S DISEASE CHAMINDA UNANTENNE RN,MS,MSN.
Parkinson’s disease by Syed Baseeruddin Alvi (09).
A Primer for Clinicians and Administrators
Parkinson's disease.
Drugs Used for Parkinson’s Disease
Parkinson’s Disease.
Parkinson Disease Parkinson disease is an idiopathic, slowly progressive, degenerative disorder characterized by resting tremor, stiffness (rigidity),
Understanding Parkinsons Disease
Movement disorder.
MOVEMENT DISORDERS.
Parkinson's disease KRZYSZTOF NICPOŃ.
“The effects of chronic changes to the functioning of the nervous system due to interference to neurotransmitter function, illustrated by the role of Dopamine.
Parkinson’s disease.
Parkinson's disease Parkinson's disease (PD) is the second-most common
The Approach to Tremor (with case examples) Praveen Dayalu MD Associate Professor Department of Neurology University of Michigan.
Atypical Parkinsonian Syndromes
WHAT I NEED TO KNOW AS A PATIENT AND A CAREGIVER
Pharmacological Management of Parkinson’s Disease
Neurodegenerative diseases
Management in Primary Care
Parkinson’s Disease Definitions Disease features Pathology
HOW DOES EXPERIENCE AFFECT BEHAVIOUR AND MENTAL PROCESSES?
Presentation transcript:

Erica Partridge Parkinson’s Disease

Definition Aetiology PD vs Parkinsonism Symptoms and signs Differentials Investigations Management Prognosis

1. What is the definition of Parkinson’s disease?

A movement disease characterised by Tremor at rest Rigidity Bradykinesia

2. Aetiology of PD

Degeneration of dopaminergic pathways in the substantia nigra

4. What is the difference between PD and Parkinsonism?

PD is used to describe idiopathic syndrome of Parkinsonism Parkinsonism is symptoms attributable to an underlying cause

5. Causes of Parkinsonism

Drug induced Any drug that blocks dopamine receptors or reduce storage of dopamine Mainly antipsychotics But also antiemetics such as metoclopramide Antihistamines – eg cyclizine 5HT3 receptor blockers – eg ondansetron Dopamine blockers eg metoclopramide, domperidone Following encephalitis Exposure to toxins – manganese dust, sever CO poisioning

6. 3 main features of PD

Tremor 4-6 hz Seen at rest – can be induced by concentration Usually apparent in one limb or one side first Rigiditiy Increase in resistance to passive movement Can produce a characteristic flexed posture Cogwheel rigidity Bradykinesia Slowness of voluntary movement Reduced arm swing Progressive reduction in amplitude of repetitive movements

7. How does PD present

Insidious onset Peak age of onset is 55-65, slightly more common in men Impairment of dexterity Progressive disorder

8. Other symptoms

Fixed facial expression Infrequent blinking Quiet voice Micrographia Gait – short shuffling steps (festination), difficulty in initiating movement and in stopping Non motor Anosmia Depression Dementia Visual hallucinations REM sleep disorders

9. Differential diagnosis

Benign essential tremor Far more common – worse on movement, rare at rest Drug or toxin induced

10. In which type of dementia do patient’s have PD symptoms?

Lewy body dementia Dementia Fluctuating levels of awareness Signs of mild PD Visual hallucinations Sleep disorgers PD dementia Dementia occuring >1 year after PD diagnosis Visual hallucinations Fluctuating lucidity

11. Diagnosis of PD

Bradykinesia plus one of following Muscular rigidity Resting tremor Postural instability Not causes by primary visual, vestibular, cerebellar or proprioceptive dysfunction

12. Investigations

Diagnosis is clinical

13. Management

Levodopa Taken with a decarboxylase inhibitor Start with low dose and build up Keep dose as low as possible N+V/loss of appetite Dopamine agonists Eg bromocriptine, cabergoline Monotherapy or adjuvant COMT inhibitors Must be taken with levodopa Eg entacapone, tolcapone

MAOBi Prevent dopamine being broken down Selegine Has amphetamine metabolites – hallucinations, nightmares, confusion so avoid in elderly Rasagiline No amphetamine metabolites

Levodopa Breakdown product Dopamine COMTMAO COMT AADC (decarboxylase) BBB

14. Other management

14. Management OT SALT Exercises to strengthen voice/help control facial expression/swallowing or drooling problems Suggest communication aids Physio PD nurse Support groups

15. Common management problems

Motor fluctuations – associated with long term L-dopa On off fluctuations – occur randomly Wearing off phenomenon – before next dose is due Involuntary movements while on – dyskinesias Axial problems Do not respond to treatment Balance, speech and gait Physio, SALT, OT Associated disease Dementia (20-40%) Depression (45%)

16. Complications

Infections Aspiration pneumonia Bed sores Poor nutrition Falls Contractures Bowel and bladder disorders

17. Prognosis

Slowly progressive with mean duration of 15 years Severity is hugely varied Some show little disability after 20 years Others severely disabled after 10 years

Explaining things to patients

What do they already know Why they need it What will happen Risks/side effects Do they have any questions? It is fine if you don’t know the answers say you will find out and get back to them Offer to give them information sheets/leaflets

References Patient UK Professional Reference NICE guidelines Parkinson’s UK website